CRISPR Therapeutics (NASDAQ:CRSP) Posts Earnings Results, Misses Estimates By $0.11 EPS

CRISPR Therapeutics (NASDAQ:CRSP) announced its quarterly earnings results on Monday. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($1.04) by ($0.11), FiscalAI reports. CRISPR Therapeutics had a negative net margin of 3,368.72% and a negative return on equity of 24.39%. The company had revenue of $12.67 million during the quarter, compared to analysts’ expectations of $14.75 million.

CRISPR Therapeutics Trading Down 2.8%

Shares of NASDAQ:CRSP traded down $1.43 on Monday, hitting $49.99. The company had a trading volume of 1,015,071 shares, compared to its average volume of 1,723,117. CRISPR Therapeutics has a 1 year low of $44.12 and a 1 year high of $64.74. The firm has a market capitalization of $4.83 billion, a price-to-earnings ratio of -10.50 and a beta of 1.76. The firm’s 50-day simple moving average is $54.19 and its two-hundred day simple moving average is $52.92. The company has a quick ratio of 17.85, a current ratio of 17.85 and a debt-to-equity ratio of 0.34.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on CRSP shares. Citizens Jmp reaffirmed a “market outperform” rating and set a $80.00 price objective on shares of CRISPR Therapeutics in a research note on Monday, August 31st. Needham & Company LLC reiterated a “buy” rating and set a $82.00 target price on shares of CRISPR Therapeutics in a research report on Monday, August 31st. Wall Street Zen raised CRISPR Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. HC Wainwright reaffirmed a “buy” rating on shares of CRISPR Therapeutics in a research note on Friday, October 9th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $55.00 target price on shares of CRISPR Therapeutics in a research note on Thursday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $65.75.

Insider Buying and Selling at CRISPR Therapeutics

In related news, General Counsel James R. Kasinger sold 1,040 shares of the stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $49.26, for a total value of $51,230.40. Following the completion of the transaction, the general counsel directly owned 95,857 shares in the company, valued at $4,721,915.82. This trade represents a 1.07% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Simeon George sold 14,514 shares of CRISPR Therapeutics stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $49.63, for a total transaction of $720,329.82. Following the transaction, the director directly owned 15,486 shares of the company’s stock, valued at approximately $768,570.18. This trade represents a 48.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 93,558 shares of company stock valued at $4,881,663 over the last 90 days. 5.20% of the stock is owned by corporate insiders.

About CRISPR Therapeutics

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. The company’s research programs are designed to address genetic diseases by precisely modifying DNA in cells, with applications across hematology, immunology, oncology, regenerative medicine and cardiovascular disease.

Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals.